A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Cited by (1,095)

Items 1,001–1,095 of 1,095

1. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research
   Shiyun Lv, Kejie Yao, Youyi Zhang, Shujia Zhu · 2022 · Neuropharmacology
2. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling.
   Emily R. Workman, Farr Niere, Kimberly F. Raab-Graham · 2013 · Neuropharmacology
3. Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy
   Zorumski, Charles F., Nagele, Peter, Mennerick, Steven, Conway, Charles R. · 2015 · Frontiers in Psychiatry
4. Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network
   Lehmann, Mick, Seifritz, Erich, Henning, Anke, Walter, Martin, Böker, Heinz, Scheidegger, Milan, Grimm, Simone · 2016 · Social Cognitive and Affective Neuroscience
5. Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
   Jollant, Fabrice, Colle, Romain, Nguyen, Thi Mai Loan, Corruble, Emmanuelle, Gardier, Alain M., Walter, Martin, Abbar, Mocrane, Wagner, Gerd · 2023 · Therapeutic Advances in Psychopharmacology
6. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
   Samalin, Ludovic, Rothärmel, Maud, Mekaoui, Lila, Gaudré-Wattinne, Emeline, Codet, Marie-Alix, Bouju, Sophie, Sauvaget, Anne · 2022 · International Journal of Psychiatry in Clinical Practice
7. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: A randomized controlled trial
   Costi, Sara, Soleimani, Laili, Glasgow, Andrew, Brallier, Jess, Spivack, John, Schwartz, Jaclyn, Levitch, Cara F., Richards, Samantha, Hoch, Megan, Stade, Elizabeth C. et al. · 2019 · Neuropsychopharmacology
8. Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
   Shinohara, Ryota, Aghajanian, George K., Abdallah, Chadi G. · 2021 · Biological Psychiatry
9. HCN Channel Targets for Novel Antidepressant Treatment
   Ku, Stacy M., Han, Ming-Hu · 2017 · Neurotherapeutics
10. The role of eEF2 kinase in the rapid antidepressant actions of ketamine
    2020 · Advances in Pharmacology
11. Significant treatment effect of add-on ketamine anesthesia in electroconvulsive therapy in depressive patients: A meta-analysis
    Li, Dian-Jeng, Wang, Fu-Chiang, Chu, Che-Sheng, Chen, Tien-Yu, Tang, Chia-Hung, Yang, Wei-Cheng, Chow, Philip Chik-keung, Wu, Ching-Kuan, Tseng, Ping-Tao, Lin, Pao-Yen · 2017 · European Neuropsychopharmacology
12. Differential regulation of GluA1 expression by ketamine and memantine
    Zhang, Ke, Yamaki, Vitor Nagai, Wei, Zhisheng, Zheng, Yu, Cai, Xiang · 2017 · Behavioural Brain Research
13. Phosphorylation of MeCP2 at Ser421 Contributes to Chronic Antidepressant Action
    Hutchinson, Ashley N., Deng, Jay V., Cohen, Sonia, West, Anne E. · 2012 · The Journal of Neuroscience
14. Region-specific glutamate changes in patients with unipolar depression
    Grimm, Simone, Luborzewski, Alexander, Schubert, Florian, Merkl, Angela, Kronenberg, Golo, Colla, Michael, Heuser, Isabella, Bajbouj, Malek · 2012 · Journal of Psychiatric Research
15. Translating a rodent measure of negative bias into humans: the impact of induced anxiety and unmedicated mood and anxiety disorders
    Aylward, Jessica, Hales, Claire, Robinson, Emma, Robinson, Oliver J. · 2020 · Psychological Medicine
16. Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer
    Zanicotti, Claudia Grott, Perez, David, Glue, Paul · 2012 · Journal of Palliative Medicine
17. Antidepressant drug action--From rapid changes on network function to network rewiring
    Rantamäki, Tomi, Yalcin, Ipek · 2016 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
18. Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action
    Suzuki, Kanzo, Kim, Ji-Woon, Nosyreva, Elena, Kavalali, Ege T., Monteggia, Lisa M. · 2021 · Cell Reports
19. Glutamate receptors in domestication and modern human evolution
    O’Rourke, Thomas, Boeckx, Cedric · 2020 · Neuroscience & Biobehavioral Reviews
20. The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
    Rubio-Casillas, Alberto, Fernández-Guasti, Alonso · 2016 · Reviews in the Neurosciences
21. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
    Esterlis, Irina, Holmes, Sophie E., Sharma, Priya, Krystal, John H., DeLorenzo, Christine · 2018 · Biological Psychiatry
22. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression
    Ho, Ming-Fen, Correia, Cristina, Ingle, James N., Kaddurah-Daouk, Rima, Wang, Liewei, Kaufmann, Scott H., Weinshilboum, Richard M. · 2018 · Biochemical Pharmacology
23. Targeting metaplasticity mechanisms to promote sustained antidepressant actions
    Brown, Kyle A., Gould, Todd D. · 2024 · Molecular Psychiatry
24. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
    Vecera, Courtney M., C. Courtes, Alan, Jones, Gregory, Soares, Jair C., Machado-Vieira, Rodrigo · 2023 · Pharmaceuticals
25. Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
    Zaytseva, Anastasiya, Bouckova, Evelina, Wiles, McKennon J, Wustrau, Madison H, Schmidt, Isabella G, Mendez-Vazquez, Hadassah, Khatri, Latika, Kim, Seonil · 2023 · eLife
26. Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects
    Rantamäki, Tomi, Kohtala, Samuel · 2020 · Pharmacological Reviews
27. Ketamine Corrects Stress-Induced Cognitive Dysfunction through JAK2/STAT3 Signaling in the Orbitofrontal Cortex
    Patton, Michael S, Lodge, Daniel J, Morilak, David A, Girotti, Milena · 2017 · Neuropsychopharmacology
28. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Niciu, Mark J., Mathews, Daniel C., Nugent, Allison C., Ionescu, Dawn F., Furey, Maura L., Richards, Erica M., Machado-Vieira, Rodrigo, Zarate, Carlos A. · 2014 · Depression and Anxiety
29. Ketamine-Enhanced Psychotherapy: Preliminary Clinical Observations on its Effects in Treating Death Anxiety
    Kolp, Eli, Young, M. Scott, Florida Mental Health Institute of University of South Florida, Friedman, Harris, University of Florida, Krupitsky, Evgeny, St. Petersburg State Pavlov Medical University, Jansen, Karl, O’Connor, Laurie-Ann, Argosy University · 2007 · International Journal of Transpersonal Studies
30. Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
    de Sousa, Rafael T., V. Zanetti, Marcus, R. Brunoni, Andre, Machado-Vieira, Rodrigo · 2015 · Current Neuropharmacology
31. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5
    Fuxe, Kjell, Borroto-Escuela, Dasiel O · 2015 · Expert Opinion on Investigational Drugs
32. Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
    Ficek, Joanna, Zygmunt, Magdalena, Piechota, Marcin, Hoinkis, Dzesika, Rodriguez Parkitna, Jan, Przewlocki, Ryszard, Korostynski, Michal · 2016 · BMC Genomics
33. The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action
    Amidfar, Meysam, Réus, Gislaine Z., Quevedo, Joao, Kim, Yong-Ku · 2018 · European Journal of Pharmacology
34. Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
    McArthur, Robert A. · 2017 · Neuroscience & Biobehavioral Reviews
35. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis
    Conley, Ashley A., Norwood, Amber E. Q., Hatvany, Thomas C., Griffith, James D., Barber, Kathryn E. · 2021 · Psychopharmacology
36. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
    Bandeira, Igor D., Lins-Silva, Daniel H., Cavenaghi, Vitor Breseghello, Dorea-Bandeira, Ingrid, Faria-Guimarães, Daniela, Barouh, Judah L., Jesus-Nunes, Ana Paula, Beanes, Graziele, Souza, Lucca S., Leal, Gustavo C. et al. · 2022 · Harvard Review of Psychiatry
37. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson’s disease.
    Bortolozzi, Analia, Manashirov, Sharon, Chen, Alon, Artigas, Francesc · 2021 · Pharmacology & Therapeutics
38. Plasticity of synapses and reward circuit function in the genesis and treatment of depression
    Thompson, Scott M. · 2023 · Neuropsychopharmacology
39. Electroconvulsive seizures stimulate the vegf pathway via mTORC1
    Elfving, Betina, Wegener, Gregers · 2012 · Synapse
40. Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
    Fancy, Farhan, Rodrigues, Nelson B., Di Vincenzo, Joshua D., Chau, Edmond H., Sethi, Rickinder, Husain, Muhammad I., Gill, Hartej, Tabassum, Aniqa, Mckenzie, Andrea, Phan, Lee et al. · 2023 · Bipolar Disorders
41. Neurobiological aspects of suicide and suicide attempts in bipolar disorder
    Mathews, Daniel, Richards, Erica, Niciu, Mark, Ionescu, Dawn, Rasimas, Joseph, Zarate, Carlos · 2013 · Translational Neuroscience
42. A predictive coding framework for understanding major depression
    Gilbert, Jessica R., Wusinich, Christina, Zarate, Carlos A. · 2022 · Frontiers in Human Neuroscience
43. Inpatient suicide in psychiatric settings: Evaluation of current prevention measures
    Chammas, Francesca, Januel, Dominique, Bouaziz, Noomane · 2022 · Frontiers in Psychiatry
44. Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression
    Wilkowska, Alina, Wiglusz, Mariusz Stanisław, Gałuszko-Wegielnik, Maria, Włodarczyk, Adam, Cubała, Wiesław Jerzy · 2021 · Frontiers in Psychiatry
45. The therapeutic potentials of Ayahuasca in the treatment of depression
    Palhano-Fontes, Fernanda, Alchieri, Joao C., Oliveira, Joao Paulo M., Soares, Bruno Lobao, Hallak, Jaime E. C., Galvao-Coelho, Nicole, de Araujo, Draulio B. · 2014 · The Therapeutic Use of Ayahuasca
46. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
    Spies, Marie, James, Gregory M, Berroterán-Infante, Neydher, Ibeschitz, Harald, Kranz, Georg S, Unterholzner, Jakob, Godbersen, Mathis, Gryglewski, Gregor, Hienert, Marius, Jungwirth, Johannes et al. · 2018 · International Journal of Neuropsychopharmacology
47. Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder
    Sharma, Lavanya P., Thamby, Abel, Balachander, Srinivas, Janardhanan, C Narayanaswamy, Jaisoorya, T.S., Arumugham, Shyam Sundar, Reddy, Y.C. Janardhan · 2020 · Asian Journal of Psychiatry
48. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression
    Averill, Lynnette A., Averill, Christopher L., Gueorguieva, Ralitza, Fouda, Samar, Sherif, Mohamed, Ahn, Kyung-Heup, Ranganathan, Mohini, D'Souza, Deepak Cyril, Southwick, Steven M., Sanacora, Gerard et al. · 2022 · Journal of Affective Disorders
49. The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
    O’Brien, Brittany, Lijffijt, Marijn, Wells, Allison, Swann, Alan C., Mathew, Sanjay J. · 2019 · Pharmaceuticals
50. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
    Artin, Hewa, Zisook, Sidney, Ramanathan, Dhakshin · 2021 · World Journal of Psychiatry
51. Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
    Sumner, Rachael L., McMillan, Rebecca, Spriggs, Meg J., Campbell, Doug, Malpas, Gemma, Maxwell, Elizabeth, Deng, Carolyn, Hay, John, Ponton, Rhys, Sundram, Frederick et al. · 2020 · European Neuropsychopharmacology
52. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-dimethyltryptamine and harmine
    Dornbierer, Dario A., Marten, Laurenz, Mueller, Jovin, Aicher, Helena D., Mueller, Michael J., Boxler, Martina, Kometer, Michael, Kosanic, Davor, von Rotz, Robin, Puchkov, Maxim et al. · 2023 · Frontiers in Pharmacology
53. Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit–Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice
    Troppoli, Timothy A., Zanos, Panos, Georgiou, Polymnia, Gould, Todd D., Rudolph, Uwe, Thompson, Scott M. · 2022 · Biological Psychiatry
54. Ketamine: stimulating antidepressant treatment?
    Malhi, Gin S., Byrow, Yulisha, Cassidy, Frederick, Cipriani, Andrea, Demyttenaere, Koen, Frye, Mark A., Gitlin, Michael, Kennedy, Sidney H., Ketter, Terence A., Lam, Raymond W. et al. · 2016 · BJPsych Open
55. Rethinking the role of TRKB in the action of antidepressants and psychedelics
    Brunello, Cecilia Anna, Cannarozzo, Cecilia, Castrén, Eero · 2024 · Trends in Neurosciences
56. Ketamine specifically reduces cognitive symptoms in depressed patients: An investigation of associated neural activation patterns
    Stippl, A., Scheidegger, M., Aust, S., Herrera, A., Bajbouj, M., Gärtner, M., Grimm, S. · 2021 · Journal of Psychiatric Research
57. Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism
    Rafało-Ulińska, Anna, Brański, Piotr, Pałucha-Poniewiera, Agnieszka · 2022 · Pharmaceuticals
58. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
    Bettini, Ezio, Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Sgrignani, Jacopo, Carignani, Corrado, Nola, Selena, Locatelli, Patrizia, Pappagallo, Marco, Inturrisi, Charles E. et al. · 2022 · Pharmaceuticals
59. Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial
    Abdallah, Chadi, Averill, Lynnette A, Gueorguieva, Ralitza, Goktas, Selin, Purohit, Prerana, Ranganathan, Mohini, D'Souza, Deepak Cyril, Formica, Richard, Southwick, Steven M, Duman, Ronald S et al. · 2018
60. Intranasal administration of transforming growth factor-β1 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling
    Wei, Yan, Chang, Lijia, Hashimoto, Kenji · 2021 · European Neuropsychopharmacology
61. Tramadol Pretreatment Enhances Ketamine-Induced Antidepressant Effects and Increases Mammalian Target of Rapamycin in Rat Hippocampus and Prefrontal Cortex
    Yang, Chun, Li, Wen-Yuan, Yu, Hai-Yin, Gao, Zhi-Qin, Liu, Xiang-Liu, Zhou, Zhi-Qiang, Yang, Jian-Jun · 2012 · Journal of Biomedicine and Biotechnology
62. Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish
    Opler, Lewis A., Opler, Mark G. A., Arnsten, Amy F. T. · 2016 · CNS Spectrums
63. Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients
    Chen, Xiaoyu, Wang, Mingqia, Hu, Yiru, Zhan, Yanni, Zhou, Yanling, Zheng, Wei, Liu, Weijian, Wang, Chengyu, Zhong, Xiaomei, Li, Hanqiu et al. · 2021 · European Archives of Psychiatry and Clinical Neuroscience
64. Ketamine Mechanism of Action: Separating the Wheat from the Chaff
    Gould, Todd D, Zanos, Panos, Zarate, Carlos A · 2017 · Neuropsychopharmacology
65. Repeated nitrous oxide exposure exerts antidepressant-like effects through neuronal nitric oxide synthase activation in the medial prefrontal cortex
    Liu, Wei, Li, Qian, Ye, Binglu, Cao, Hang, Shen, Fuyi, Xu, Zhendong, Du, Weijia, Guo, Fei, Liu, Jinqi, Li, Tianyu et al. · 2020 · Frontiers in Psychiatry
66. Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamine
    Grieco, Steven F., Qiao, Xin, Johnston, Kevin G., Chen, Lujia, Nelson, Renetta R., Lai, Cary, Holmes, Todd C., Xu, Xiangmin · 2021 · Translational Psychiatry
67. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis
    Zhou, Yanling, Liu, Weijian, Zheng, Wei, Wang, Chengyu, Zhan, Yanni, Lan, Xiaofeng, Zhang, Bin, Zhang, Cuiling, Ning, Yuping · 2020 · Journal of Affective Disorders
68. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways
    Ren, Li · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
69. All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
    Freudenberg, Florian, Reif-Leonhard, Christine, Dawson, Gerard R., McKernan, Ruth M., Reif, Andreas · 2025 · Pharmacological Research
70. Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain
    Réus, Gislaine Z., Stringari, Roberto B., Rezin, Gislaine T., Fraga, Daiane B., Daufenbach, Juliana F., Scaini, Giselli, Benedet, Joana, Rochi, Natália, Streck, Emílio L., Quevedo, João · 2012 · Journal of Neural Transmission
71. Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression
    Zhang, Fan, Wang, Chengyu, Lan, Xiaofeng, Li, Weicheng, Ye, Yanxiang, Liu, Haiyan, Hu, Zhibo, You, Zerui, Zhou, Yanling, Ning, Yuping · 2023 · Journal of Affective Disorders
72. Using an experimental medicine model to understand the antidepressant potential of the <i>N</i> -Methyl-D-aspartic acid (NMDA) receptor antagonist memantine
    Pringle, A, Parsons, E, Cowen, LG, McTavish, SF, Cowen, PJ, Harmer, CJ · 2012 · Journal of Psychopharmacology
73. Dysfunctional heteroreceptor complexes as novel targets for the treatment of major depressive and anxiety disorders
    Pérez de la Mora, Miguel, Borroto-Escuela, Dasiel O., Crespo-Ramírez, Minerva, Rejón-Orantes, José del Carmen, Palacios-Lagunas, Daniel Alejandro, Martínez-Mata, Magda K., Sánchez-Luna, Daniela, Tesoro-Cruz, Emiliano, Fuxe, Kjell · 2022 · Cells
74. Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents
    Watanabe, Mai, Marcy, Brian, Hiroki, Ayano, Watase, Hirotaka, Kinoshita, Kohnosuke, Iijima, Michihiko, Marumo, Toshiyuki, Zarate, Carlos A, Chaki, Shigeyuki · 2022 · International Journal of Neuropsychopharmacology
75. Ketamine for Depression: An Update
    Murrough, James W. · 2016 · Biological Psychiatry
76. NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
    Hasegawa, Yuto, Zhu, Xiaolei, Kamiya, Atsushi · 2019 · Journal of Clinical Investigation
77. Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression
    Gilbert, Jessica R., Gerner, Jessica L., Burton, Courtney R., Nugent, Allison C., Zarate, Carlos A., Ballard, Elizabeth D. · 2022 · Journal of Affective Disorders
78. Are 24-hour motor activity patterns associated with continued rapid response to ketamine?
    Duncan Jr, Wallace C, Slonena, Elizabeth E, Hejazi, Nadia S, Brutsche, Nancy, Park, Lawrence T, Henter, Ioline D, Ballard, Elizabeth D, Zarate Jr, Carlos A · 2018 · Neuropsychiatric Disease and Treatment
79. Prospective association of psychological pain and hopelessness with suicidal thoughts
    Ballard, Elizabeth D., Farmer, Cristan A., Gerner, Jessica, Bloomfield-Clagett, Bartholt, Park, Lawrence T., Zarate, Carlos A. · 2022 · Journal of Affective Disorders
80. Blinding and expectancy confounds in psychedelic randomised controlled trials
    Muthukumaraswamy, Suresh, Forsyth, Anna, Lumley, Thomas · 2021
81. Advances in the study of NMDA receptors in depression pathogenesis and the antidepressant efficacy of their antagonists
    Chen, Mingrui, Jin, Jingyan, Bi, Hongsheng, Zhang, Yihan, Sun, Mingyuan, Li, Xiaobai, Wang, Yan · 2025 · Asian Journal of Psychiatry
82. Classical conditioning of antidepressant placebo effects in mice
    Krimmel, Samuel R., Zanos, Panos, Georgiou, Polymnia, Colloca, Luana, Gould, Todd D. · 2020 · Psychopharmacology
83. Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
    Ballard, Elizabeth D., Fields, Jessica, Farmer, Cristan A., Zarate, Carlos A. · 2021 · Suicide and Life-Threatening Behavior
84. Self-Care Practices with Psychedelics–A Qualitative Study of Users’ Perspectives
    Soares, Carla Mendes, Leite, Ângela, Pinto, Marta · 2023 · Journal of Psychoactive Drugs
85. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
    Scala, Mauro, Fabbri, Chiara, Fusar-Poli, Paolo, Di Lorenzo, Giorgio, Ferrara, Maria, Amerio, Andrea, Fusar-Poli, Laura, Pichiecchio, Anna, Asteggiano, Carlo, Menchetti, Marco et al. · 2024 · CNS Spectrums
86. Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
    Gómez de San José, Nerea, Goossens, Julie, Al Shweiki, Mhd Rami, Halbgebauer, Steffen, Oeckl, Patrick, Steinacker, Petra, Danzer, Karin M., Graf, Heiko, Schönfeldt-Lecuona, Carlos, Belbin, Olivia et al. · 2022 · Journal of Psychiatric Research
87. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine
    Bloomfield-Clagett, Bartholt, Ballard, Elizabeth D, Greenstein, Deanna K, Wilkinson, Samuel T, Grunebaum, Michael F, Murrough, James W, Mathew, Sanjay J, Phillips, Jennifer L, Fava, Maurizio, Sanacora, Gerard et al. · 2022 · International Journal of Neuropsychopharmacology
88. Polypharmacy- Purpose, Benefits and Limitations
    Grover, Douglas, Tom, Michelle, Maguire, Gerald, Stahl, Stephen · 2022 · Current Medicinal Chemistry
89. Population Pharmacokinetic and Exposure–dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients
    Cosson, Valérie, Schaedeli‐Stark, Franziska, Arab‐Alameddine, Mona, Chavanne, Clarisse, Guerini, Elena, Derks, Michael, Mallalieu, Navita L. · 2018 · Clinical and Translational Science
90. Suicide prevention and ketamine: insights from computational modeling
    Charlton, Colleen E., Karvelis, Povilas, McIntyre, Roger S., Diaconescu, Andreea O. · 2023 · Frontiers in Psychiatry
91. Clinical indicators of the suicide crisis and response to ketamine
    Ballard, Elizabeth D., Neely, Lucinda, Waldman, Laura, Greenstein, Dede, Zarate, Carlos A. · 2025 · Journal of Affective Disorders
92. Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
    Venero, César · 2015 · Cognitive Enhancement
93. MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses
    Piazza, Michelle K., Weit, Abigael R., Kavalali, Ege T., Neul, Jeffrey L., Monteggia, Lisa M. · 2025 · iScience
94. Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis
    Xie, Jingqiang, Pu, Chunying, Sun, Mingyue · 2026 · Frontiers in Psychiatry
95. From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
    Domany, Yoav, Solomon-Shashua, Aviv · 2026 · Neuroscience &amp; Biobehavioral Reviews